Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
European Journal of Clinical Pharmacology|January 4, 2020
Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatinMarta Karaźniewicz-Łada, Dagmara Krzyżańska, Dorota Danielak, et al.Scandinavian Journal of Clinical and Laboratory Investigation|March 10, 2017
Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assaysDorota Danielak, Anna Komosa, Aleksandra Tomczak, et al.International Journal of Pharmaceutics|March 14, 2025
Gastric stress events impact the bioavailability of a poorly soluble weak base dabigatran from pellet-filled capsules: An outcome from pharmacokinetic simulations based on biorelevant dissolution testing, machine learning, and a novel timewise first-order dissolution modelMichał Romański, Marcela Staniszewska, Daria Myslitska, et al.European Journal of Clinical Pharmacology|September 16, 2017
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metaboliteDorota Danielak, Marta Karaźniewicz-Łada, Anna Komosa, et al.Molecular Pharmaceutics|April 3, 2024
In Vitro Simulation of the Fasted Gastric Conditions and Their Variability to Elucidate Contrasting Properties of the Marketed Dabigatran Etexilate Pellet-Filled Capsules and Loose PelletsMarcela Staniszewska, Daria Myslitska, Michał Romański, et al.Pharmaceutics|August 26, 2023
A Rational Approach to Predicting Immediate Release Formulation Behavior in Multiple Gastric Motility Patterns: A Combination of a Biorelevant Apparatus, Design of Experiments, and Machine LearningMarcela Staniszewska, Michał Romański, Sebastian Polak, et al.International Journal of Pharmaceutics|November 24, 2023
An extension of biorelevant fed-state dissolution tests to clinical pharmacokinetics - A study on gastrointestinal factors influencing rivaroxaban exposure and efficacy in atrial fibrillation patientsMichał Romański, Joanna Giebułtowicz, Elżbieta Gniazdowska, et al.AAPS Pharmscitech|June 4, 2020
Physiologically Based Dissolution Testing in a Drug Development Process-a Case Study of a Successful Application in a Bioequivalence Study of Trazodone ER Formulations Under Fed ConditionsDorota Danielak, Bartłomiej Milanowski, Krzysztof Wentowski, et al.Pharmaceutics|June 2, 2021
Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 Agonist for a First-in-Human Clinical TrialEwelina Juszczyk, Kamil Kisło, Paweł Żero, et al.Journal of Pharmaceutical and Biomedical Analysis|June 24, 2020
A novel open source tool for ELISA result analysisDorota Danielak, Grzegorz Banach, Juliusz Walaszczyk, et al.Pageof 4